ImmuCell (ICCC) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmuCell in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICCC shares.
View ICCC analyst ratings or view top-rated stocks.

ImmuCell's stock was trading at $6.10 on January 1st, 2023. Since then, ICCC stock has decreased by 14.9% and is now trading at $5.19.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ICCC earnings forecast.

ImmuCell Co. (NASDAQ:ICCC) announced its earnings results on Thursday, August, 12th. The biotechnology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.10. The biotechnology company had revenue of $4.54 million for the quarter. ImmuCell had a negative trailing twelve-month return on equity of 17.30% and a negative net margin of 33.23%.

ImmuCell issued an update on its first quarter earnings guidance on Saturday, April, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.45 million-$3.45 million, compared to the consensus revenue estimate of $5.40 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Biocept (BIOC), Amarin (AMRN), CRISPR Therapeutics (CRSP), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Pfizer (PFE).

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

ImmuCell's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.59%), Cresset Asset Management LLC (1.30%), Dimensional Fund Advisors LP (0.84%), Empire Financial Management Company LLC (0.54%), Overbrook Management Corp (0.42%) and Prosperity Planning Inc. (0.21%).
View institutional ownership trends.

Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ICCC stock can currently be purchased for approximately $5.19.

ImmuCell (NASDAQ:ICCC) has a market capitalization of $40.22 million and generates $18.57 million in revenue each year. The biotechnology company earns $-2,490,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The official website for the company is www.immucell.com. The biotechnology company can be reached via phone at (207) 878-2770, via email at iccc@lythampartners.com, or via fax at 207-878-2117.